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Abstract: Cutaneous field of cancerization (CFC) is caused in
part by the carcinogenic effect of the cyclobutane pyrimidine
dimers CPD and 6-4 photoproducts (6-4PPs). Photoreactivation
is carried out by photolyases which specifically recognize and
repair both photoproducts. The study evaluates the molecular
effects of topical application of a film-forming medical device
containing photolyase and UV filters on the precancerous field
in AK from seven patients. Skin improvement after treatment
was confirmed in all patients by histopathological and molecular
assessment. A gene set analysis showed that skin recovery was
associated with biological processes involved in tissue
homoeostasis and cell maintenance. The CFC response was
associated with over-expression of the CPI-17 gene, and a
dependence on the initial expression level was observed
(P = 0.001). Low CPI-17 levels were directly associated with pro-
inflammatory genes such as TNF (P = 0.012) and IL-1B
(P = 0.07). Our results suggest a role for CPI-17 in restoring
skin homoeostasis in CFC lesions.
Key words: actinic keratoses – CPI-17 – cutaneous field of cancerization –
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Background
Cutaneous field of cancerization (CFC) is associated with genomic
alterations due to the carcinogenic effect of sun exposure (1) and
comprises actinic keratoses (AKs) and squamous cell carcinomas
(SCCs) (2). UV radiation, particularly UVB, promotes the produc-
tion of cyclobutane pyrimidine dimers (CPDs) and 6-4 photo-
products (6-4PPs) which subsequently interfere with biological
processes that are critical for cell viability (3). The nucleotide exci-
sion repair (NER) system is employed by mammal cells to remove
UV-induced DNA damage (4). However, whereas 6-4PPs are effi-
ciently recognized and removed by the NER system, CPDs recog-
nition and removal is poor (5,6). Many organisms have an
additional repair mechanism named photoreactivation, which is
carried out by photolyases which specifically recognize and repair
either CPDs or 6-4PPs (7). The potential of DNA photolyases in
skin cancer prevention has been increasingly recognized. Beneficial
effects after transferring a CPD photolyase into mammals have
been obtained in transgenic mice (8). Transgenic expression of
photolyases showed a 40% increase in CPD lesion repair,
improved resistance against UV-induced effects suppressing the
formation of skin carcinomas. Furthermore, topical application of
liposome formulations with CPD photolyases onto human skin
provides protection against UVB-induced damage (9).
Questions addressed
We explored the molecular effects of topical application of Eryfo-
tona AK-NMSC (Eryf-AK; ISDIN, Barcelona, Spain), a film-
forming medical device containing Repairsomes® (photolyase in
liposomes and UV filters), in patients with CFC.
Experimental design
For experimental design and procedures see Data S1.
Results
Three of seven patients with CFC (AK Pretreatment biopsies) pre-
sented a complete histological clearance, one patient presented his-
tological clearance in more than 80% of the sample, and three
additional cases presented partial histological improvement
associated with inflammation. Based upon the histopathology
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assessment after Eryf-AK treatment, the subjects were classified as
fast responders (FR) versus slow-partial responders (PR) (Table S1).
The differential gene expression analysis of CFC pretreatment
versus posttreatment assessment failed to detect deregulated genes
after correction for multiple testing. However, over-expressions of
CPI-17 gene (2.8-fold increase, P = 0.039) and WDR72 gene
(1.9-fold increase, P = 0.040) were detected in FR subgroup.
CPI-17 expression differences between FR and PR subgroups were
confirmed by RT-PCR (P = 0.001) (Figure 1a). In contrast, no
significant differences (P = 0.211) were observed for WDR72
(Figure 1b). Initial CPI-17 levels were higher in FR than PR
patients (P = 0.045; Figure 1a).
Pathological conditions such as inflammation modulate CPI-17
expression (10). Thus, expression of TNF and IL-1B cytokines were
evaluated. FR showed lower expression levels of TNF (P = 0.012)
and IL-1B (P = 0.07) after Eryf-AK (Figure 1c,d). Posttreatment PR
lesions still showed a high IL-1B expression level (P = 0.038).
Gene set analysis identified 150 biological functions (P < 0.005;
Table S2) associated with CFC, which were classified in four major
biological clusters: ‘generation of reactive oxygen species’, ‘mecha-
nisms involved in DNA repair’, ‘cell division process’ and ‘lipids’.
Sixty six processes were associated with Eryf-AK treatment
(P < 0.005, Table S3), which were grouped as ‘cell communication
and signalling’, ‘cell adhesion’ and ‘tissue development’.
Gene set analysis according to treatment response identified 24
GOs over-expressed in FR subgroup mostly involved in cell
response and homoeostasis and 28 GO’s associated with PR
lesions which were related to inflammation and cytokine produc-
tion, apoptosis and lipid metabolic processes (Table 1).
Conclusions
We identified biological processes associated with CFC such as
ROS production and DNA damage repair processes that may be
induced in part by CPDs and/or lipid metabolism. Lipid content
changes are important in AK and BCC (11). After treatment, we
found over-expression of fundamental processes related to tissue
reconstitution (cell communication, signalling and adhesion).
Based on treatment response, treated PR biopsies showed an
over-expression of apoptotic process, lipid metabolism, cytokine
production and inflammation which are directly related to AK.
Inflammation is important for AK maintenance which is abolished
by the topical use of diclofenac combined with hyaluronic acid
through a selective inhibition of COX2 (12–14). The histopatho-
logical evaluation showed the presence of AK in at least 20% of
the biopsy specimen from PR patients. In treated FR subgroup,
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Figure 1. Values of relative quantification of selected genes and markers by
subtype of patients (fast responders versus partial responders) and time of
treatment (prior pretreatment or posttreatment): (a) Values of relative
quantification of CPI-17 (2DDCt). *P-values <0.05, **P-values <0.001. (b) Values of
relative quantification of WDR72 (2DDCt). P-values pretreatment lesion = 0.631;
P-value posttreatment lesion = 0.211. (c) Values of relative quantification of TNFa
(2DDCt). *P-values <0.05; P-value posttreatment lesion = 0.447. (d) Values of
relative quantification of IL-1B (2DDCt). *P-values <0.05; P-value pretreatment
lesion = 0.070.
Table 1. Gene ontology terms detected by gene set analysis in posttreatment biopsies by response subgroup
Response to treatment1 Gene Ontology terms (ID and P-value)2
Fast responders (FR) Cell-cell signalling (0007267, P = 3.02E-06); Embryonic development (0009790, P = 1.15E-05); Cell development (0048468, P = 1.46E-05);
Secretion (0046903, P = 2.10E-05); Regulation of secretion (0051046, P = 1.22E-04); Muscle contraction (0006936, P = 1.87E-04);
Chemical homoeostasis (0048878, P = 2.44E-04); Anterior/posterior pattern formation (0009952, P = 3.05E-04); Cellular homoeostasis
(0019725, P = 4.93E-04); Embryonic development ending in birth or egg hatching (0009792, P = 6.73E-04); Chordate embryonic
development (0043009, P = 1.8E-03); Homoeostatic process (0042592, P = 1.30E-03); Ion homoeostasis (0050801, P = 1.53E-03),
Secretion by cell (0032940, P = 1,53E-03); Response to steroid hormone stimulus (0048545, P = 2.00E-03); Cell fate commitment
(0045165, P = 2.19E-03); Response to hypoxia (0001666, P = 2.22E-03); Cellular chemical homoeostasis (0055082, P = 2.23E-03);
Regulation of blood vessel size (0050880, P = 2.76E-03); Smooth muscle contraction (0006939, P = 3.26E-03); Response to inorganic
substance (0010035, P = 4.09E-03); Response to hormone stimulus (0009725, P = 4.37E-03); Neurological system process (0050877,
P = 3.08E-02); Cell morphogenesis (0000902, P = 1.17E+00)
Partial responders (PR) Organic acid metabolic process (0006082, P = 3.35E-18); Carboxylic acid metabolic process (0019752, P = 3.35E-18); Lipid metabolic
process (0006629 P = 1.28E-13); Cellular lipid metabolic process (0044255, P = 8.13E-13); Lipid biosynthetic process (0008610,
P = 2.09E-09); Regulation of immune response (0050776, P = 1.09E-08); Steroid metabolic process (0008202, P = 7.70E-08); Regulation
of interleukin-6 production (0032675, P = 2.07E-07); Regulation of cytokine production (0001817, P = 2.07E-07); Positive regulation of
immune response (0050778, P = 2,81E-06); Carbohydrate metabolic process (0005975, P = 3.67E-05); Leucocyte migration (0050900,
P = 4.62E-05); Neutral lipid metabolic process (0006638, P = 1.65E-04); Glycerol ether metabolic process (0006662, P = 1.65E-04);
Regulation of lipid metabolic process (0019216, P = 1.80E-04); Positive regulation of cytokine production (0001819, P = 1.83E-04);
Response to drug (0042493, P = 3.12E-04); cellular carbohydrate metabolic process (0044262, P = 3.61E-04); Locomotory behaviour
(0007626, P = 3.91E-04); Lipid storage (0019915, P = 8.60E-04); Response to organic substance (0010033, P = 2.62E-03); Interleukin-12
production (0032615, P = 2.95E-03); Apoptosis (0006915, P = 2.96E-03); Negative regulation of cytokine production (0001818,
P = 3.01E-03); Programmed cell death (0012501, P = 3.68E-03); Response to molecule of bacterial origin (0002237, P = 3.96E-03);
Regulation of programmed cell death (0043067, P = 4.06E-03); Amine metabolic process (0009308, P = 4.74E-03)
1Patients were classified as fast responders and partial responders based on the histopathology assessment after Eryf-AK treatment (see Table S1).
2The ID numbers and the P-values are indicated for each GO.
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which correlates with the improvement in histopathological mea-
sures (Puig et al. 2012; submitted for publication).
CPI-17 over-expression was associated with normal phenotype
recovery. CPI-17 is one of the major Ser/Thr phosphatase iso-
forms, and its activation suppresses the MYPT1-PP1d activity
resulting in muscle contraction (10). CIP-17 expression is detected
in multiple cell types (15–17) involved in several processes
(16,18). MYTP1 inhibition results in more prominent focal adhe-
sions and absence of cell migration (19). CPI-17 is directly associ-
ated with focal adhesion kinases (20) and located at focal
adhesions in fibroblasts and keratinocytes (21). MYPT1-PP1d
complex can also regulate the dephosphorylation of retinoblas-
toma protein (pRb) (22) which shows a deregulated activation in
AK. We observed that inflammation modulates CPI-17 expression
in CFC. Thus, processes such as DNA damage or ROS production
may cause CPI-17 down-deregulation, which could lead to uncon-
trolled MYPT1-PP1d activity. Deregulated phosphatase activity in
CFC may affect cell motility, cell adhesion and cell cycle control
mediated by pRb.
In conclusion, 1-month Eryf-AK treatment improved the field
of cancerization and restored normal phenotype in at least a sub-
set of samples, through CPI-17 up-regulation.
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Abstract: Epidermal growth factor (EGF) is not only a cell growth
stimulant but also has a catagen-inducing effect. Because
chemotherapeutic agents primarily damage anagen hair follicles, it
would be important to investigate whether catagen inducers have
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